Teijin (3401) Q4 2026 earnings summary

Executive summary

• FY2025 revenue declined by ¥132.3 billion (13.2%) to ¥873.2 billion, with adjusted operating income down ¥1.8 billion (6.6%) to ¥25.8 billion, mainly due to the transfer of the composites business in North America and lower performance in Materials and Others segments.

• Loss attributable to owners of parent was ¥88.0 billion, primarily from impairment losses in aramid and Healthcare businesses, compared to a profit of ¥28.3 billion in the prior year.

• Healthcare segment improved adjusted operating income, driven by growth in rented home medical devices and pharmaceutical licensing income.

• EBITDA was ¥86.1 billion; ROE was -22.1% and ROIC was 2.6%.

• Annual dividend maintained at ¥50/share.

Financial highlights

• FY2025 revenue: ¥873.2 billion (down 13.2% year-over-year).

• Adjusted operating income: ¥25.8 billion (down 6.6% year-over-year).

• EBITDA: ¥86.1 billion (down ¥12.1 billion year-over-year).

• Loss attributable to owners of parent: ¥88.0 billion (down ¥116.4 billion year-over-year).

• Basic EPS: -¥456.33 (down from ¥147.15 in FY2024).

Outlook and guidance

• FY2026 revenue forecast: ¥850.0 billion (down 2.7% year-over-year).

• Adjusted operating income forecast: ¥30.0 billion (up 16.4%).

• Profit attributable to owners of parent forecast: ¥45.0 billion; ROE: 12%; ROIC: 3%.

• Dividend forecast unchanged at ¥50/share.

• ROE expected to recover to 12%; ROIC to rise to 3%.